Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis

Seminars in Diagnostic Pathology

Volumn 32, Issue 5, 2015, Pages 325-333

  Sholl, Lynette M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Fluorescence in situ hybridization; Gene sequencing; Immunohistochemistry; Non small cell carcinoma; Predictive biomarkers

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; SCATTER FACTOR RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ALK GENE; ARTICLE; CARCINOGENICITY; EGFR GENE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LKB1 GENE; LUNG ADENOCARCINOMA; MET GENE; MOLECULAR PATHOLOGY; MUTATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; RET GENE; ROS1 GENE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MOLECULAR DIAGNOSIS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS;

ADENOCARCINOMA; BIOMARKERS, TUMOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM PROTEINS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84940447536     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2015.02.019     Document Type: Article

References (63)

1. Lindeman N.I., Cagle P.T., Beasley M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Mol Diagn 2013, 15(4):415-453.
2. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181.
3. Sobol R.E., Astarita R.W., Hofeditz C., et al. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987, 79(3):403-407.
4. Kim E.S., Neubauer M., Cohn A., et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013, 14(13):1326-1336.
5. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 6(12):4885-4892.
6. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
7. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
8. Lee J.K., Hahn S., Kim D.W., et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. J Am Med Assoc 2014, 311(14):1430-1437.
9. Motoi N., Szoke J., Riely G.J., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32(6):810-827.
10. Yasuda H., Park E., Yun C.H., et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013, 5(216):216ra177.
11. Sholl L.M., Xiao Y., Joshi V., et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010, 133(6):922-934.
12. Kato Y., Peled N., Wynes M.W., et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010, 5(10):1551-1558.
13. Brevet M., Arcila M., Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12(2):169-176.
14. Bondgaard A.L., Hogdall E., Mellemgaard A., Skov B.G. High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. Mod Pathol 2014, 27(12):1590-1598.
15. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
16. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.
17. Dziadziuszko R., Wynes M.W., Singh S., et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012, 7(2):340-347.
18. Sholl L., Sun H., Ligon A., Butaney M., Janne P.A., Rodig S.J. MET copy number by dual color brightfield in situ hybridization and fluorescence in situ hybridization correlates with met protein expression in lung adenocarcinomas. Mod Pathol 2013, 26(S2). 467A. [Abstract].
19. Bar K. Roche halts study on experimental cancer drug MetMab. 〈〉 2014 Accessed 10.01.14. http://www.reuters.com/article/2014/03/03/us-roche-metmab-idUSBREA220SQ20140303.
20. Koeppen H., Yu W., Zha J., et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib ± onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014, 20(17):4488-4498.
21. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
22. ten Berge R.L., Oudejans J.J., Ossenkoppele G.J., et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 2000, 53(6):445-450.
23. Lawrence B., Perez-Atayde A., Hibbard M.K., et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000, 157(2):377-384.
24. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
25. Shaw A.T., Yeap B.Y., Solomon B.J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12(11):1004-1012.
26. Rodig S.J., Mino-Kenudson M., Dacic S., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15(16):5216-5223.
27. Sholl L.M., Weremowicz S., Gray S.W., et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013, 8(3):322-328.
28. Cutz J.C., Craddock K.J., Torlakovic E., et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol 2014, 9(9):1255-1263.
29. Suehara Y., Arcila M., Wang L., et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012, 18(24):6599-6608.
30. Selinger C.I., Rogers T.M., Russell P.A., et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013, 26(12):1545-1553.
31. Wu Y.C., Chang I.C., Wang C.L., et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 2013, 8(8):e70839.
32. Yang J.J., Zhang X.C., Su J., et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 2014, 20(5):1383-1392.
33. Takeuchi K., Soda M., Togashi Y., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18(3):378-381.
34. Rimkunas V.M., Crosby K.E., Li D., et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012, 18(16):4449-4457.
35. Shaw A.T., Ou S.H., Bang Y.J., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014, 371(21):1963-1971.
36. Sholl L.M., Sun H., Butaney M., et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 2013, 37(9):1441-1449.
37. Cha Y.J., Lee J.S., Kim H.R., et al. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One 2014, 9(7):e103333.
38. Mescam-Mancini L., Lantuejoul S., Moro-Sibilot D., et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 2014, 83(2):168-173.
39. Sasaki H., Shimizu S., Tani Y., et al. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med 2012, 1(1):68-75.
40. Lee S.E., Lee B., Hong M., et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol 2014.
41. Drilon A., Wang L., Hasanovic A., et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013, 3(6):630-635.
42. Cardarella S., Ogino A., Nishino M., et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013, 19(16):4532-4540.
43. Gautschi O., Peters S., Zoete V., et al. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer 2013, 82(2):365-367.
44. Peters S., Michielin O., Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 2013, 31(20):e341-e344.
45. Routhier C.A., Mochel M.C., Lynch K., Dias-Santagata D., Louis D.N., Hoang M.P. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013, 44(11):2563-2570.
46. Berger A.H., Imielinski M., Duke F., et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 2014.
47. Vaishnavi A., Capelletti M., Le A.T., et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013, 19(11):1469-1472.
48. Fernandez-Cuesta L., Plenker D., Osada H., et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 2014, 4(4):415-422.
49. Mazieres J., Peters S., Lepage B., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013, 31(16):1997-2003.
50. Grob T.J., Kannengiesser I., Tsourlakis M.C., et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol 2012, 25(12):1566-1573.
51. Gandhi L., Bahleda R., Tolaney S.M., et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014, 32(2):68-75.
52. Ardini E., Bosotti R., Borgia A.L., et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 2014, 8(8):1495-1507.
53. Janku F., Hong D.S., Fu S., et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014, 6(2):377-387.
54. Dedes K.J., Wetterskog D., Mendes-Pereira A.M., et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010, 2(53):53ra75.
55. Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2(5):401-404.
56. Xu C., Fillmore C.M., Koyama S., et al. Loss of LKB1 and PTEN leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25(5):590-604.
57. McFadden D.G., Papagiannakopoulos T., Taylor-Weiner A., et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014, 156(6):1298-1311.
58. Yanagawa N., Leduc C., Kohler D., et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J Thorac Oncol 2012, 7(10):1513-1521.
59. Marsit C.J., Zheng S., Aldape K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36(7):768-776.
60. Pallares J., Bussaglia E., Martinez-Guitarte J.L., et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005, 18(5):719-727.
61. Zhang B.G., Li J.F., Yu B.Q., Zhu Z.G., Liu B.Y., Yan M. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep 2012, 27(4):1019-1026.
62. Janne P.A., Shaw A.T., Pereira J.R., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14(1):38-47.
63. Chen Z., Cheng K., Walton Z., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483(7391):613-617.